Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9447106 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(11 years from now) | |
US10570139 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(11 years from now) | |
US11142528 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(11 years from now) | |
US10927117 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(14 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11591340 | BEIGENE | NA |
Aug, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
Orphan Drug Exclusivity (ODE) | Sep 14, 2028 |
New Indication (I) | Sep 14, 2024 |
NCE-1 date: 2023-11-15
Market Authorisation Date: 14 November, 2019
Treatment: For the treatment of patients with waldenstrom's macroglobulinemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); Treatment of adult patients with chronic lymphocytic leukemia; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; Treatment of adult patients with small lymphocytic lymphoma
Dosage: CAPSULE;ORAL
12
United States
5
China
3
Japan
3
Australia
2
Singapore
2
Brazil
2
Mexico
2
Korea, Republic of
2
EA
2
South Africa
2
Lithuania
2
Canada
2
Hungary
2
Israel
2
European Union
1
Portugal
1
Spain
1
Croatia
1
IB
1
New Zealand
1
Taiwan, Province of China
1
Hong Kong
1
Cyprus
1
Slovenia
1
Poland
1
RS
1
Denmark
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic